These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18564618)

  • 1. Early phase Technology Assessment of nanotechnology in oncology.
    Retèl VP; Hummel MJ; van Harten WH
    Tumori; 2008; 94(2):284-90. PubMed ID: 18564618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review on early technology assessments of nanotechnologies in oncology.
    Retèl VP; Hummel MJ; van Harten WH
    Mol Oncol; 2009 Dec; 3(5-6):394-401. PubMed ID: 19540817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics.
    Retèl VP; Bueno-de-Mesquita JM; Hummel MJ; van de Vijver MJ; Douma KF; Karsenberg K; van Dam FS; van Krimpen C; Bellot FE; Roumen RM; Linn SC; van Harten WH
    Int J Technol Assess Health Care; 2009 Jan; 25(1):73-83. PubMed ID: 19126254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanotechnology: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(19):1-43. PubMed ID: 23074489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scenario drafting to anticipate future developments in technology assessment.
    Retèl VP; Joore MA; Linn SC; Rutgers EJ; van Harten WH
    BMC Res Notes; 2012 Aug; 5():442. PubMed ID: 22894140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scenario drafting for early technology assessment of next generation sequencing in clinical oncology.
    Joosten SEP; Retèl VP; Coupé VMH; van den Heuvel MM; van Harten WH
    BMC Cancer; 2016 Feb; 16():66. PubMed ID: 26851938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methodology of constructive technology assessment in health care.
    Douma KF; Karsenberg K; Hummel MJ; Bueno-de-Mesquita JM; van Harten WH
    Int J Technol Assess Health Care; 2007; 23(2):162-8. PubMed ID: 17493301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].
    Della Palma P; Moresco L; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(5 Suppl 3):e1-43. PubMed ID: 23139174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Over-, under- and misuse of pain treatment in Germany.
    Dietl M; Korczak D
    GMS Health Technol Assess; 2011 Apr; 7():Doc03. PubMed ID: 21522485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncology from an HTA and Health Economic Perspective.
    Francois C; Zhou J; Pochopien M; Achour L; Toumi M
    Recent Results Cancer Res; 2019; 213():25-38. PubMed ID: 30543005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
    Brettschneider C; Lühmann D; Raspe H
    GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individual health services.
    Schnell-Inderst P; Hunger T; Hintringer K; Schwarzer R; Seifert-Klauss VR; Gothe H; Wasem J; Siebert U
    GMS Health Technol Assess; 2011; 7():Doc05. PubMed ID: 21966301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corporate social responsibility for nanotechnology oversight.
    Kuzma J; Kuzhabekova A
    Med Health Care Philos; 2011 Nov; 14(4):407-19. PubMed ID: 21626458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness.
    Lindenberg M; Retèl V; Rohaan M; van den Berg J; Haanen J; van Harten W
    BMC Cancer; 2020 Jul; 20(1):712. PubMed ID: 32736535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Technology assessment for new oncology drugs.
    Jönsson B
    Clin Cancer Res; 2013 Jan; 19(1):6-11. PubMed ID: 23288370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of programmes as part of primary prevention demonstrated on the example of cardiovascular diseases and the metabolic syndrome.
    Korczak D; Dietl M; Steinhauser G
    GMS Health Technol Assess; 2011 Apr; 7():Doc02. PubMed ID: 21468290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic and societal dimensions of nanotechnology-enabled drug delivery.
    te Kulve H; Rip A
    Expert Opin Drug Deliv; 2013 May; 10(5):611-22. PubMed ID: 23406414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health Technology Assessment Challenges in Oncology: 20 Years of Value in Health.
    Kim H; Goodall S; Liew D
    Value Health; 2019 May; 22(5):593-600. PubMed ID: 31104740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrast-enhanced ultrasound and/or colour duplex ultrasound for surveillance after endovascular abdominal aortic aneurysm repair: a systematic review and economic evaluation.
    Brazzelli M; Hernández R; Sharma P; Robertson C; Shimonovich M; MacLennan G; Fraser C; Jamieson R; Vallabhaneni SR
    Health Technol Assess; 2018 Dec; 22(72):1-220. PubMed ID: 30543179
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.